Flutamide administration at 500 mg dialy has similar effects on serum testosterone to 750 mg daily

Jeremiah C. Murphy, Sandy Srinivas, Martha Kennedy Terris

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A prior comparison of 750 mg flutamide daily to 500 mg daily with an LHRH analog or orchiectomy showed no difference in effect on prostate specific antigen (PSA). However, any difference was likely masked by hypogonadism from concomitant LHRH analog or orchiectomy. We sought to evaluate different flutamide dosing schedules without this confounding factor. We recruited 50 men with advanced prostate cancer who elected to receive hormonal therapy to be randomized to 1 of 3 flutamide treatment groups: 1) 250 mg once daily, 2) 250 mg twice daily, or 3) 250 mg 3 times daily for 3 months, after which the therapy of their choice was instituted. Serum samples at the initiation of therapy and at the 1- and 3-month time point were assessed for PSA, testosterone, liver function tests, hematology, and renal function. Prostate volume, androgen deficiency symptoms, and a compliance diary were also recorded. Testosterone and PSA levels show a dose-dependent response to flutamide monotherapy. Loss of libido and erectile dysfunction occurred in all 3 treatment groups, with a trend toward worsening sexual function with higher flutamide dosing, but this trend did not reach statistical significance. Prostate volumes decreased by an average of 34.3% in the patients receiving 250 mg flutamide 3 times daily, 27.8% in patients receiving 250 mg flutamide twice daily, and 19.2% in those receiving a once daily dose of 250 mg flutamide. There was a significant difference between the once daily group and the 3 times daily group (P = .047). Flutamide at 500 mg did not result in significant changes in testosterone, PSA, prostate volume, or androgen deficiency symptoms compared to 750 mg daily after 3 months.

Original languageEnglish (US)
Pages (from-to)630-634
Number of pages5
JournalJournal of Andrology
Volume25
Issue number4
DOIs
StatePublished - Jan 1 2004

Fingerprint

Flutamide
Testosterone
Serum
Prostate-Specific Antigen
Prostate
Orchiectomy
Gonadotropin-Releasing Hormone
Androgens
Therapeutics
Libido
Hypogonadism
Liver Function Tests
Erectile Dysfunction
Hematology
Compliance
Prostatic Neoplasms
Appointments and Schedules
Kidney

Keywords

  • Androgen deprivation
  • Antiandrogen
  • Hormone
  • PSA
  • Prostate neoplasm

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Reproductive Medicine
  • Endocrinology
  • Urology

Cite this

Flutamide administration at 500 mg dialy has similar effects on serum testosterone to 750 mg daily. / Murphy, Jeremiah C.; Srinivas, Sandy; Terris, Martha Kennedy.

In: Journal of Andrology, Vol. 25, No. 4, 01.01.2004, p. 630-634.

Research output: Contribution to journalArticle

@article{179fa81e694a40db894834b163cdc58f,
title = "Flutamide administration at 500 mg dialy has similar effects on serum testosterone to 750 mg daily",
abstract = "A prior comparison of 750 mg flutamide daily to 500 mg daily with an LHRH analog or orchiectomy showed no difference in effect on prostate specific antigen (PSA). However, any difference was likely masked by hypogonadism from concomitant LHRH analog or orchiectomy. We sought to evaluate different flutamide dosing schedules without this confounding factor. We recruited 50 men with advanced prostate cancer who elected to receive hormonal therapy to be randomized to 1 of 3 flutamide treatment groups: 1) 250 mg once daily, 2) 250 mg twice daily, or 3) 250 mg 3 times daily for 3 months, after which the therapy of their choice was instituted. Serum samples at the initiation of therapy and at the 1- and 3-month time point were assessed for PSA, testosterone, liver function tests, hematology, and renal function. Prostate volume, androgen deficiency symptoms, and a compliance diary were also recorded. Testosterone and PSA levels show a dose-dependent response to flutamide monotherapy. Loss of libido and erectile dysfunction occurred in all 3 treatment groups, with a trend toward worsening sexual function with higher flutamide dosing, but this trend did not reach statistical significance. Prostate volumes decreased by an average of 34.3{\%} in the patients receiving 250 mg flutamide 3 times daily, 27.8{\%} in patients receiving 250 mg flutamide twice daily, and 19.2{\%} in those receiving a once daily dose of 250 mg flutamide. There was a significant difference between the once daily group and the 3 times daily group (P = .047). Flutamide at 500 mg did not result in significant changes in testosterone, PSA, prostate volume, or androgen deficiency symptoms compared to 750 mg daily after 3 months.",
keywords = "Androgen deprivation, Antiandrogen, Hormone, PSA, Prostate neoplasm",
author = "Murphy, {Jeremiah C.} and Sandy Srinivas and Terris, {Martha Kennedy}",
year = "2004",
month = "1",
day = "1",
doi = "10.1002/j.1939-4640.2004.tb02834.x",
language = "English (US)",
volume = "25",
pages = "630--634",
journal = "Journal of Andrology",
issn = "0196-3635",
publisher = "American Society of Andrology Inc.",
number = "4",

}

TY - JOUR

T1 - Flutamide administration at 500 mg dialy has similar effects on serum testosterone to 750 mg daily

AU - Murphy, Jeremiah C.

AU - Srinivas, Sandy

AU - Terris, Martha Kennedy

PY - 2004/1/1

Y1 - 2004/1/1

N2 - A prior comparison of 750 mg flutamide daily to 500 mg daily with an LHRH analog or orchiectomy showed no difference in effect on prostate specific antigen (PSA). However, any difference was likely masked by hypogonadism from concomitant LHRH analog or orchiectomy. We sought to evaluate different flutamide dosing schedules without this confounding factor. We recruited 50 men with advanced prostate cancer who elected to receive hormonal therapy to be randomized to 1 of 3 flutamide treatment groups: 1) 250 mg once daily, 2) 250 mg twice daily, or 3) 250 mg 3 times daily for 3 months, after which the therapy of their choice was instituted. Serum samples at the initiation of therapy and at the 1- and 3-month time point were assessed for PSA, testosterone, liver function tests, hematology, and renal function. Prostate volume, androgen deficiency symptoms, and a compliance diary were also recorded. Testosterone and PSA levels show a dose-dependent response to flutamide monotherapy. Loss of libido and erectile dysfunction occurred in all 3 treatment groups, with a trend toward worsening sexual function with higher flutamide dosing, but this trend did not reach statistical significance. Prostate volumes decreased by an average of 34.3% in the patients receiving 250 mg flutamide 3 times daily, 27.8% in patients receiving 250 mg flutamide twice daily, and 19.2% in those receiving a once daily dose of 250 mg flutamide. There was a significant difference between the once daily group and the 3 times daily group (P = .047). Flutamide at 500 mg did not result in significant changes in testosterone, PSA, prostate volume, or androgen deficiency symptoms compared to 750 mg daily after 3 months.

AB - A prior comparison of 750 mg flutamide daily to 500 mg daily with an LHRH analog or orchiectomy showed no difference in effect on prostate specific antigen (PSA). However, any difference was likely masked by hypogonadism from concomitant LHRH analog or orchiectomy. We sought to evaluate different flutamide dosing schedules without this confounding factor. We recruited 50 men with advanced prostate cancer who elected to receive hormonal therapy to be randomized to 1 of 3 flutamide treatment groups: 1) 250 mg once daily, 2) 250 mg twice daily, or 3) 250 mg 3 times daily for 3 months, after which the therapy of their choice was instituted. Serum samples at the initiation of therapy and at the 1- and 3-month time point were assessed for PSA, testosterone, liver function tests, hematology, and renal function. Prostate volume, androgen deficiency symptoms, and a compliance diary were also recorded. Testosterone and PSA levels show a dose-dependent response to flutamide monotherapy. Loss of libido and erectile dysfunction occurred in all 3 treatment groups, with a trend toward worsening sexual function with higher flutamide dosing, but this trend did not reach statistical significance. Prostate volumes decreased by an average of 34.3% in the patients receiving 250 mg flutamide 3 times daily, 27.8% in patients receiving 250 mg flutamide twice daily, and 19.2% in those receiving a once daily dose of 250 mg flutamide. There was a significant difference between the once daily group and the 3 times daily group (P = .047). Flutamide at 500 mg did not result in significant changes in testosterone, PSA, prostate volume, or androgen deficiency symptoms compared to 750 mg daily after 3 months.

KW - Androgen deprivation

KW - Antiandrogen

KW - Hormone

KW - PSA

KW - Prostate neoplasm

UR - http://www.scopus.com/inward/record.url?scp=3042736735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042736735&partnerID=8YFLogxK

U2 - 10.1002/j.1939-4640.2004.tb02834.x

DO - 10.1002/j.1939-4640.2004.tb02834.x

M3 - Article

C2 - 15223852

AN - SCOPUS:3042736735

VL - 25

SP - 630

EP - 634

JO - Journal of Andrology

JF - Journal of Andrology

SN - 0196-3635

IS - 4

ER -